At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 80 enrolled
Drug / intervention
Vascepa +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Effect of Vascepa on Progression of Coronary Atherosclerosis in Persons With Elevated Triglycerides (200-499) on Statin Therapy
Lundquist Institute for Biomedical Innovation at Harbor-UCLA Medical Center·interventional·Posted Oct 6, 2016·Updated Feb 21, 2023
In Brief
A Phase 4 clinical trial evaluating Vascepa and placebo for Hypertriglyceridemia. Completed, enrolled 80 participants across 2 sites.
Detailed Summary
Effect of Vascepa on Progression of Coronary Atherosclerosis in Persons with Elevated Triglycerides (200-499) on Statin Therapy. The study is to determine progression rates of low attenuation plaque under influence of Vascepa as compared to placebo.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertriglyceridemia
CountriesUnited States
CollaboratorsIntermountain Research and Medical Foundation
Timeline
Phase 4CompletedFinished
2017201820192020202120222023202420252026
First PostedOct 2016
Enrollment StartMar 2017
Primary CompletionMay 2020
Study CompletionAug 2020
TodayJul 2026
First PostedOct 6, 2016
Enrollment StartMar 28, 2017
Primary CompletionMay 15, 2020
Study CompletionAug 15, 2020
TodayJul 2, 2026
Enrollment to primary: 3.1 yearsPosted 9.7 years ago
Interventions
Vascepadrug
Vascepa is a an Eicosapentaenoic acid (EPA), an omega-3 polyunsaturated fatty acid.
placebodrug
placebo